Skip to main content
Download PDF

Effectiveness of the online Acceptance and Commitment Therapy intervention “Embrace Pain” for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy: study protocol for a randomized controlled trial

Trials volume 23, Article number: 642 (2022) Cite this article

Abstract

Background

About 30% of cancer survivors suffer from chemotherapy-induced peripheral neuropathy (CIPN) ≥6 months after completion of chemotherapy. This condition, for which treatment options are scarce, comes with limitations in daily life functioning and decreased quality of life. The current study examines the effectiveness of an online self-help intervention based on Acceptance and Commitment Therapy (ACT) in comparison to a waiting list condition (WLC) to deal with CIPN. In addition, it examines which factors moderate effects and to what extent the effects differ between guided and unguided ACT intervention.

Methods

A two-parallel, non-blinded randomized controlled trial (RCT) will be carried out. Adult cancer survivors who experience painful CIPN for at least 3 months and completed chemotherapy at least 6 months ago will be recruited (n=146). In the intervention condition, participants will follow an 8-week self-management course containing 6 modules regarding psychoeducation and ACT processes, including therapeutic email guidance. By means of text and experiential exercises, supplemented with illustrations, metaphors, and audio files, people will learn to carry out value-oriented activities in their daily life with pain. Participants will learn new ways of coping with pain, including reducing pain avoidance and increasing pain acceptance. Participants in the WLC will be invited to follow the intervention without therapeutic guidance 5 months after start. Pain interference is the primary outcome, while psychological distress, quality of life, CIPN symptom severity, pain intensity, psychological flexibility, mindfulness skills, values-based living, and pain catastrophizing will serve as secondary outcomes. All outcome measures will be evaluated at inclusion and baseline, early-intervention, mid-intervention, post-treatment, and 3- and 6-month post-treatment. Qualitative interviews will be conducted post-treatment regarding experiences, usage, usability, content fit, and satisfaction with the intervention.

Discussion

This study will provide valuable information on the effectiveness of an online self-help intervention based on ACT versus WLC for chronic painful CIPN patients.

Trial registration

ClinicalTrials.gov NCT05371158. Registered on May 12, 2022.

Protocol version: version 1, 24-05-2022

Peer Review reports

Background

The number of cancer survivors continues to grow [1,2,3,4,5] as the population ages, early detection through screening rises, and cancer survival rates improve [6]. Many of these survivors face long-term side effects of cancer and its treatment, whereby their quality of life (QoL) is strongly affected [1, 7]. Chemotherapy can cause multiple disabling long-term side effects like chemotherapy-induced peripheral neuropathy (CIPN) [8]. CIPN can occur due to the use of certain chemotherapeutic agents, such as taxanes, platinum compounds, and vinca alkaloids [9]. CIPN presents itself with symptoms such as tingling, numbness, cramps, and aching or burning pain in the hands and feet, which can also spread to arms and legs [10,11,12]. Up to 80% of cancer survivors suffers from CIPN 1 month after chemotherapy, which stabilizes to around 30% at 6 months or longer after chemotherapy [7, 8, 13,14,15,16]. This prevalence differs between cancer types (range 10–60%). As the application of chemotherapy in cancer treatment is rising, CIPN is likely to become one of the most common long-term side effects for cancer survivors [17]. CIPN is a very limiting condition, as a systematic review has shown that CIPN negatively influences QoL in adult cancer survivors [7]. Patients can experience impaired QoL due to CIPN up to 11 years after chemotherapy, caused by the decreased performance of regular activities, depressive symptoms, and poor sleep quality [18,19,20,21]. In addition, it has been shown that specifically painful CIPN is associated with lower QoL compared to non-painful CIPN [22].

In order to improve the patients’ QoL, cognitive behavioral therapies (CBT), like third-generation CBTs as Acceptance & Commitment Therapy (ACT), are increasingly used in global cancer care [23, 24]. ACT helps patients to shift focus towards engaging in personally valuable activities by increasing pain acceptance [25] and has been shown to be effective for other types of chronic pain [26]. Although the effectiveness of online ACT interventions has not yet been investigated for chronic painful CIPN patients, a previous study found that treatment with online CBT positively affected pain intensity in this patient group, creating positive expectations for treatment with online ACT as well [27]. Traditional face-to-face psychological therapies have some drawbacks, such as high costs, not being accessible or hardly available, having to travel to the therapist, negative stigma, and high psychological burden [27, 28]. Due to developments in the field of eHealth, these obstacles can be mitigated [27,28,29]. That is, with the use of online self-management interventions, patients are able to receive psychological therapy whenever and wherever they would like to, without having to travel to a therapist [27, 28]. Online self-management interventions offer the additional benefit of augmented protection of patients’ anonymity and privacy [29].

Even though online interventions are relatively new, several such interventions have demonstrable effectivity in improving QoL in cancer patients and survivors [28, 30,31,32]. A randomized controlled trial (RCT) has shown that the use of an online CBT intervention significantly improved CIPN pain intensity and may be effective [27]. Furthermore, research has shown that online interventions based on ACT are capable of improving pain intensity, pain interference, pain catastrophizing, disability, depression, anxiety, psychological inflexibility, and QoL in chronic pain patients with a variety of pain diagnoses (e.g., fibromyalgia, rheumatoid arthritis, and back complaints) [33, 34]. These findings suggest that an online self-help intervention based on ACT might be effective for adult cancer survivors with chronic painful CIPN as well. However, effects may differ between patients, since previous research has shown factors such as pain intensity, depressive and anxiety symptoms, and emotional well-being to predict the effectiveness of online ACT for chronic pain [35], and the extent to which patients benefit from the online intervention may hence vary. Furthermore, there may also be differences in the effectiveness with different types of the online intervention, namely with or without guidance. Earlier research has shown that guidance, including feedback, explanations, motivations and reminders, improves treatment effects compared to unguided interventions [36, 37]. The primary aim of this study researching the online intervention named ‘Embrace Pain’ is to reduce pain interference in cancer survivors with chronic painful CIPN. To study this, three objectives have been formulated:

  • Objective 1: To examine the effectiveness of an online self-help intervention based on ACT for reducing pain interference in cancer survivors with chronic painful CIPN in a randomized controlled trial (RCT) and compare this to a waiting list condition (WLC).

  • Objective 2: To examine which baseline demographic, clinical, and psychosocial factors may moderate the effectiveness of an online self-help intervention based on ACT.

  • Objective 3: To examine the extent to which effects differ between guided and unguided versions of the online self-help intervention based on ACT.

Methods

Study design

An RCT will be carried out with two parallel, non-blinded groups. Participants will be involved in the study for a duration of 8 months from the first to the last measurement. Outcome measures will be collected at baseline (T0), early-intervention (T1; 3 weeks after baseline), mid-intervention (T2; 6 weeks after baseline), directly at the end of intervention (T3; 2 months after baseline), and through two follow-up measurements (T4; 3 months after the intervention, T5; 6 months after intervention). A flowchart of the study is shown in Fig. 1.

Fig. 1
figure 1

Flowchart

Full size image

Study population

Inclusion criteria consist of (a) age of 18 years or older and (b) identified by a clinician or self as having painful sensations (i.e., aching, burning, “pins-and-needles”, shock-like, painful tingling, numbness, cramps) bilaterally in the feet/legs and/or hands/arms for at least 3 months. Furthermore, (c) a score of 3 or higher on an 11-point pain intensity scale (Numeric Rating Scale), (d) the pain was not present prior to receiving chemotherapy, (e) chemotherapy ended at least 6 months ago, and (f) a score of 1 or higher on EORTC QLQ–CIPN20. Exclusion criteria are (a) enrollment in psychological treatment related to cancer, pain, or psychological disorders upon entry; (b) new chemotherapy scheduled during study participation; (c) no access to the Internet/no email address; (d) not enough time to follow the intervention (2 h per week); and (e) according to patient’s own perception no problems with the Dutch language.

Recruitment

Patients will be recruited through a flyer with a QR code and a link to a website. These flyers will be distributed in various ways (in the Netherlands): online media (e.g., Kanker.nl, Facebook groups for neuropathy, patient associations), hospital waiting rooms (e.g., oncology departments, AYA centers, pain clinics), and through other healthcare providers (e.g., oncological foot care providers). Interested patients can visit the recruitment website where they can read more information and sign up if interested.

When a patient is interested in participation, the patient will receive an information letter and an informed consent form by mail, sent by a research assistant. The informed consent also includes information regarding the collection and use of participant data in follow-up studies. Afterwards, the participant will receive a questionnaire (T0a) regarding inclusion criteria, to examine whether the participant is eligible to participate. Additionally, patients must achieve certain scores on several questionnaires, namely Numeric Rating Scale ≥2 and EORTC QLQ–CIPN20 ≥1. If the questionnaire from T0a shows that respondents are not suitable for participation, they will be notified with a rejection and along with it the reason for rejection based on the relevant inclusion or exclusion criterion.

Randomization

When the patient is admitted to the study, the patient will receive confirmation of participation, the result of randomization, and the baseline questionnaire (T0b). Patients will be randomized to receive either ACT or WLC. The study will stratify by age and sex by means of block-wise randomization. An online generator will be used for this. Randomization will be performed by a research associate.

Intervention

The experimental condition includes an online psychological intervention with therapist email guidance based on ACT. The intervention can be worked through by the patient from home or at another location of choice, in a webpage or app by logging in with an email and self-created password. Participants receive a welcome letter from the supervisor. It consists of 6 modules which can be worked through in 8 weeks. The intervention primarily consists of text and experiential exercises, complemented with illustrations, metaphors, and audio (mp3) files. Before starting the module, participants read an introduction about the training. The first module includes psychoeducation on neuropathic pain and CIPN (Table 1). Participants will be provided with information to familiarize themselves with intervention goals and mindfulness exercises central to ACT. In subsequent modules, participants will learn about the aversive effects of pain avoidance, gain insight into their personal values, and work on pain acceptance. Throughout the intervention, participants will exercise to recognize unhelpful thoughts about their pain and learn the difference between the subjective (judging) and objective self, create activities that align with values, and think about concrete actions to prevent relapse. When access to the online environment is terminated, participants can no longer view the online environment or communicate with the supervisor. However, participants can always continue to view the session they submitted.

Table 1 Schematic overview of modules of the ACT intervention
Full size table

Participants in the experimental condition will receive guidance from Psychology master’s students from Tilburg University, who will be first trained and then supervised by a licensed healthcare psychologist. In addition, they receive supervision in the first weeks of providing guidance. Also, they will always have the possibility to ask for advice from a licensed clinical psychologist during the intervention. There will also be a backup in case of possible psychological problems that require more help. In that case, the licensed clinical psychologist will be informed and asked for advice. Guidance of participants will occur via email. Contact will be without obligation. It is possible to send an email every week in the protected environment of the online intervention, which complies with all privacy conditions as stated by the GDPR. Guidance is mainly intended for feedback related to the exercises made, answering questions about the content, and maintaining motivation to continue with the intervention. Here the choice lies with the participant, but facilitators will continue to encourage questions throughout the training.

Waiting list condition

The control condition includes a WLC. At 5 months after start (i.e., T4) participants in the WLC receive the opportunity to follow the intervention without email guidance by a therapist. They neither receive a welcome letter at the start, which means that they only read the introduction about the training before starting.

Outcomes

Questionnaires will be completed online via the PROFILES Registry [38]. Patients will receive reminders via email to promote participant retention and complete follow-up. A complete overview of enrolment, interventions, and outcome measurements is shown in Table 2.

Table 2 Schedule of enrolment, interventions, and assessments
Full size table

Primary outcome

Pain interference will be measured using the Multidimensional Pain Inventory, Dutch language version (MPI-DLV) – subscale Interference [39, 40]. The MPI consists of statements rated on a 7-point Likert scale ranging from 0 (no change) to 6 (a lot of change). The subscale Interference focuses on psychosocial aspects of chronic pain, such as functioning in work, homework, and recreational and social activities. The scale consists of 11 items and has been translated/validated into Dutch [39].

Secondary outcomes

Quality of life will be measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30) [41]. This is a validated 30-item self-report screening scale for QoL in cancer patients including a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) including five subscales (i.e., physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning) [41].

CIPN symptom severity will be measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ–CIPN20) [42]. This questionnaire is intended to be used as a supplement to the EORTC QLQ-C30. It assesses CIPN-related symptoms as well as functional limitations related to CIPN. The questionnaire has been validated and includes 20 items on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) including three subscales (i.e., sensory, motor, and autonomic symptoms) [43].

Pain intensity will be measured with the Numeric Rating Scale (NRS-11) [44]. This is based on International Association for the Study of Pain (IASP) recommendations for measures in clinical trials on chronic pain [44]. This questionnaire has been validated and includes 2 items on a 11-point Likert scale ranging from 0 (no pain) to 10 (the worst pain possible) [45].

Psychological distress will be measured using the Hospital Anxiety and Depression Scale (HADS) [46, 47]. This is based on IASP recommendations for measures in clinical trials on chronic pain [44]. The HADS is a validated 14-item self-report screening scale (ranging from 0 to 3) including two subscales (i.e., anxiety and depression symptoms) [46, 47].

Pain catastrophizing will be measured using the Pain Catastrophizing Scale (PCS) [48]. This questionnaire includes three subscales (i.e., rumination, magnification, and helplessness). It consists of 13 items on a 5-point Likert scale ranging from 0 (not at all) to 4 (always) and has been validated [48].

Psychological flexibility will be measured with the Psychological Inflexibility in Pain Scale (PIPS) [49, 50]. This is a validated 12-item measurement, including two subscales (i.e., avoidance and cognitive fusion) [51]. It consists of a 7-point Likert scale, ranging from 0 (never true) to 6 (always true).

Mindfulness will be measured using the Freiburg Mindfulness Inventory (FMI) [52]. This validated measurement consists of 14 items with two subscales (i.e., presence and acceptance) [52]. It includes a 4-point Likert scale, ranging from 0 (rarely) to 3 (almost always).

Values-based living will be measured with the Engaged Living Scale (ELS) [53]. This is a validated 16-item measurement, consisting of two subscales (i.e., valued living and life fulfillment) [53]. It includes a 5-point Likert scale, ranging from 0 (completely disagree) to 4 (completely agree).

Intervention evaluation

Intervention evaluation includes 15 questions regarding the evaluation of the intervention. It includes questions regarding amount of use and overall satisfaction with the content and guidance, which was based on an earlier RCT studying an online ACT intervention [33]. Overall satisfaction will be measured using the Client Satisfaction Questionnaire (CSQ-8) [54]. Also, participants will grade the intervention on a scale from 1 (extremely poor) to 10 (excellent).

Process outcomes

Technical data regarding usage of the intervention will be gathered, namely moment when session was first viewed, moment when session was finished, moment of message sent to supervisor, and moment of feedback given by supervisor. This enables evaluation of adherence to the intervention and information about the use of guidance. Once all participants have completed the online training, Karify will make this data available. Karify is the eHealth platform in which the online intervention was build (ISO 27001 and NEN 7510 certified).

Other outcomes

Qualitative data on intervention experiences and satisfaction will be collected by means of interviews with some participants after completion of the intervention. In this way, it will be possible to examine experiences, usage, usability, content fit of intervention with complaints, and satisfaction. Specifically, both participants who adhered and did not adhere to the intervention will be interviewed. Patients adhered to the intervention if all sessions were completed (i.e., based on data retrieved from Karify) and a minimum of 2 h per week was spent on the intervention (i.e., self-reported). Participants are informed about this by the information letter and informed consent form. As a starting point, 4 patients in each group (i.e., adherent and non-adherent) will be interviewed. New interviews will be done until saturation is reached.

Participant characteristics

Socio-demographic factors are assessed, including sex, marital status, having children, educational level, and work. Clinical information will be examined as well, including year of diagnosis, tumor type, other cancer treatments besides chemotherapy, CIPN characteristics (i.e., days per week, medication used to treat CIPN), long-term consequences of cancer (other than CIPN), and psychological problems. Comorbidities in the last 12 months will be examined using the Self-administered Comorbidity Questionnaire (SCQ) [55].

Sample size calculation

Per group, 51 participants during follow-up measurements are necessary to detect minimal effect sizes of interest (d = .50) on the primary outcome. This is based on earlier findings on effectiveness of online and face-to-face ACT intervention for chronic pain [33, 34]. The power will be high enough (p = 1-beta = .80) to find significant effects in a two-sided test at alpha = .05. As found in previous online ACT interventions, a drop-out rate of 30% needs to be considered. G*Power calculations revealed that 73 participants per group are needed at baseline, which means that 146 participants are needed in total.

Statistical analysis

Primary analyses

Significant differences at baseline between the conditions will be checked by performing one-way ANOVA’s and chi-square tests.

Effects of the intervention on all outcomes will be assessed by performing intention-to-treat analyses using general linear mixed models. Baseline to post-intervention and 3- and 6-month follow-up differences will be used as repeated measures, with treatment (2 levels), time (3 levels) and their first-order interactions as fixed factors. Confidence intervals of 95% will be calculated for all outcomes. Drop-out and non-adherence are relatively common in online interventions [56]. Therefore, secondary analyses will be performed to examine effects on outcome variables for participants who adhered to the intervention (i.e., all session completed and self-reported minimum of 2 h per week spent on intervention). At post-intervention and follow-up, effect sizes (Cohen’s d) will be calculated using means and standard deviations. Effect sizes of 0.80 are considered large, effect sizes of 0.50 are evaluated as moderate, and effect sizes of 0.20 are considered small [57].

Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations will be followed to evaluate the proportion of participants showing clinically significant change [58]. Clinical improvement will be assessed with missing values imputed by the Expectation Maximization-algorithm. Proportions of clinically improved participants and Chi-square tests will assess statistically significant differences in the proportions for the two conditions. It will be calculated for (a) pain interference (MPI – Interference), (b) pain intensity (NRS), and (c) CIPN symptom severity (EORTC QLQ – CIPN 20). A decrease of at least 0.6 standard deviation will be assessed as evidence of clinically significant change for the MPI – Interference scale, based on the IMMPACT guidelines [58]. Decreases of 20% or higher in pain intensity (NRS) will be assessed as minimum and moderate changes. No specific IMMPACT guidelines exist for the HADS. Therefore, a distribution-based decrease of at least 1 standard error of the mean is recommended [58].

Secondary analyses

To assess predictors of effects, steps of a study on predictors of change during CBT for chronic pain will be followed [59]. Pain interference at 3-month follow-up will be used as indicator of treatment effect. Using the PROCESS macro for SPSS [60], linear regression models will be applied (two-tailed). Predictor variables may include sex, age, educational level, number of comorbidities, time since CIPN onset, CIPN symptom severity (EORTC QLQ – CIPN20), quality of life (EORTC QLQ-C30), pain intensity (NRS), psychological distress (HADS), psychological inflexibility (PIPS), mindfulness (FMI-NL), valued based living (ELS), and pain catastrophizing (PCS). They will be selected based on theoretical and empirical considerations.

To assess differences in effects between the guided and unguided version of the intervention, independent samples t-tests and a two-stage hierarchical multiple regression analysis for each primary and secondary outcome will be conducted. Baseline to 3-month follow-up change will be used as the dependent variable. The independent variable will be an intervention dummy variable. Baseline score on the respective outcome measure will be used as control variable. Effect sizes for both conditions will be computed to indicate differences in the magnitude of the effects of online ACT with and without email counseling.

Interview analyses

Qualitative data will be used to gain further insight in the intervention effects, usage, usability, content fit of intervention with complaints, and satisfaction. All interviews will be recorded and transcribed verbatim. Thematic analysis in Atlas Ti 8.0 will be used to analyze the data. Following transcription, two researchers will independently (re)read a set of 3–4 interviews and perform inductive coding followed by a discussion of disparities. One researcher will further code the rest of the interviews using a codebook that will be generated from the first round of coding, adding new codes along the way, and discussing outcomes of coding with the second researcher.

Ethical considerations

This study protocol has been reviewed and approved by the Medical Research Ethics Committee Brabant, the Netherlands (reference number: NL78436.028.21). If there are protocol modifications, all relevant parties will be informed. Tilburg University has insurance for participants for compensation in the unlikely event that participants are harmed from trial participation.

Data security

Each participant will be assigned a study number, which guarantees confidentiality and anonymity. Only the research assistant will be able to connect the study numbers to the participants. Data will be stored in a secure location (PROFILES registry) for 15 years. PROFILES data is freely available (FAIR principles) for non-commercial scientific research trough www.profilesregistry.nl [38].

Output

Trial results will be published in (inter)national peer reviewed scientific journals and will be communicated to the stakeholder group, the Dutch Cancer Society, and Netherlands Comprehensive Cancer Organisation (IKNL). Presentations will be held at (inter)national conferences.

Discussion

Chronic painful CIPN is a very limiting long-term consequence of chemotherapy that many adult cancer survivors suffer from, resulting in a greatly reduced QoL. Since treatment options are limited, online self-help therapy could offer support to these patients. This study aims to evaluate effectiveness of an online self-help intervention based on ACT. It could provide an entry point for the development of psychological treatment for cancer patients suffering from other forms of cancer pain, which is a major, growing cancer survivorship issue that is highly under recognized.

Trial status

Recruitment started in December 2021. Estimated Primary Completion Date is July 1, 2023.

Availability of data and materials

The research team will have access to the final trial coded dataset. They can access it at any time and there is nothing contractually preventing that. The research assistant will have access to all data, both coded and uncoded.

Abbreviations

ACT:

Acceptance and Commitment Therapy

CBT:

Cognitive Behavioral Therapy

CIPN:

Chemotherapy-induced peripheral neuropathy

PROFILES Registry:

Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship Registry

RCT:

Randomized controlled trial

WLC:

Waiting list condition

References

  1. Heins M, Schellevis F, Rijken M, Van Der Hoek L, Korevaar J. Determinants of increased primary health care use in cancer survivors. J Clin Oncol. 2012;30(33):4155–60.

    Article  PubMed  Google Scholar 

  2. Hulvat MC. Cancer incidence and trends. Surg Clin North Am. 2020. https://doi.org/10.1016/j.suc.2020.01.002.

  3. Elferink MAG, Van Steenbergen LN, Krijnen P, Lemmens VEPP, Rutten HJ, Marijnen CAM, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer. 2010;46(8):1421–9.

    Article  CAS  PubMed  Google Scholar 

  4. Van Steenbergen LN, Lemmens VEPP, Rutten HJT, Wymenga ANM, Nortier JWR, Janssen-Heijnen MLG. Increased adjuvant treatment and improved survival in elderly stage III colon cancer patients in the Netherlands. Ann Oncol. 2012;23(11):2805–11.

    Article  PubMed  CAS  Google Scholar 

  5. Sukel MPP, van de Poll-Franse LV, Nieuwenhuijzen GAP, Vreugdenhil G, Herings RMC, Coebergh JWW, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer. 2008;44(13):1846–54.

    Article  PubMed  Google Scholar 

  6. Signaleringscommissie Kanker van KWF Kankerbestrijding. Kanker in Nederland tot 2020. Trends en prognoses. 2011. Available from: https://www.medischcontact.nl/web/file?uuid=5e7f00e5-4bb9-4635-8b40-b00aa89805c2&owner=8b0a181f-3a46-40cc-b794-9de61bc0db3f. Cited 2020 May 26.

  7. Mols F, Beijers T, Vreugdenhil G, Van De Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.

    Article  PubMed  Google Scholar 

  8. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–70.

    Article  PubMed  Google Scholar 

  9. Kannarkat G, Lasher E. Neurology DS-C opinion in, 2007 U. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–25 Available from: https://journals.lww.com/spinejournal/00019052-200712000-00021.fulltext. Cited 2020 Apr 22.

    Article  CAS  PubMed  Google Scholar 

  10. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17.

    Article  CAS  PubMed  Google Scholar 

  11. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care. 2011;5(1):1–7 Available from: https://journals.lww.com/co-supportiveandpalliativecare/fulltext/2011/03000/Chemotherapy_induced_neuropathic_pain.2.aspx?casa_token=oPhXlOLc9PEAAAAA:D6OL01B0fnOoPS6DUz1OCRI1eFScUOh-SxOKuHbXhw9pN4lUBQ46kJj-Rii57-UbXzsKA64zZNsBg4iyN-JvIsDIp_ZXbc. Cited 2021 Jul 2.

    Article  PubMed  Google Scholar 

  12. Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: The value of neuroprotective strategies. Neth J Med. 2012;70(1):18–25.

    CAS  PubMed  Google Scholar 

  13. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer. 2010;116(10):2322–31.

    CAS  PubMed  Google Scholar 

  14. Bonhof CS, Mols F, Vos MC, Pijnenborg JMA, Boll D, Vreugdenhil G, et al. Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: a longitudinal study. Gynecol Oncol. 2018;149(3):455–63.

    Article  CAS  PubMed  Google Scholar 

  15. Eckhoff L, Knoop A, Jensen M, Cancer ME-EJ of, 2015 U. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer. 2015;51:292–300 Available from: https://www.sciencedirect.com/science/article/pii/S0959804914011496. Cited 2020 Apr 28.

    Article  CAS  PubMed  Google Scholar 

  16. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22(7):1999–2007.

    Article  CAS  PubMed  Google Scholar 

  18. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21:3307–13.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010;14(3):E22–8.

    Article  PubMed  Google Scholar 

  20. Mols F, Beijers AJM, Lemmens V, van den Hurk CJ, Vreugdenhil G, Van De Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2-to 11-year colorectal cancer survivors: results from the population-based PROFILES registry development of an EORTC cancer survivorship assessment strategy View project LIVE. Artic J Clin Oncol. 2013;31(21):2699–707.

    Article  Google Scholar 

  21. Bonhof CS, Van de Poll-Franse LV, de Hingh IH, Nefs G, Vreugdenhil G, Mols F. Association between peripheral neuropathy and sleep quality among colorectal cancer patients from diagnosis until 2-year follow-up: results from the PROFILES registry. J Cancer Surviv. 2021. https://doi.org/10.1007/s11764-021-01130-7.

  22. Bonhof CS, Trompetter HR, Vreugdenhil G, van de Poll-Franse LV, Mols F. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry. Support Care Cancer. 2020;28(12):5933–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hulbert-Williams NJ, Storey L, Wilson KG. Psychological interventions for patients with cancer: psychological flexibility and the potential utility of Acceptance and Commitment Therapy. Eur J Cancer Care. 2015;24(1):15–27.

    Article  CAS  Google Scholar 

  24. Feros DL, Lane L, Ciarrochi J, Blackledge JT. Acceptance and Commitment Therapy (ACT) for improving the lives of cancer patients: a preliminary study. Psychooncology. 2013;22(2):459–64.

    PubMed  Google Scholar 

  25. Hayes SC, Luoma J, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: Model, processes and outcomes. Behav Res Ther. 2006;44(1):1–25.

    Article  PubMed  Google Scholar 

  26. McCracken LM, Vowles KE. Acceptance and commitment therapy and mindfulness for chronic pain model, process, and progress. Am Psychol. 2014;69(2):178.

    Article  PubMed  Google Scholar 

  27. Knoerl R, Smith EML, Barton DL, Williams DA, Holden JE, Krauss JC, et al. Self-guided online cognitive behavioral strategies for chemotherapy-induced peripheral neuropathy: a multicenter, pilot, randomized, wait-list controlled trial. J Pain. 2018;19(4):382–94.

    Article  PubMed  Google Scholar 

  28. Børøsund E, Mirkovic J, Clark M, Ehlers S, Andrykowski M, Bergland A, Westeng M, Solberg Nes L. A stress management app intervention for cancer survivors: design, development, and usability testing. JMIR Form Res. 2018;2(2):e19. https://doi.org/10.2196/formative.9954.

  29. Gainsbury S, Blaszczynski A. Online self-guided interventions for the treatment of problem gambling. Int Gambl Stud. 2011;11(3):289–308.

    Article  Google Scholar 

  30. Slev VN, Mistiaen P, Pasman HRW, Leeuw IMV, van Uden-Kraan CF, Francke AL. Effects of eHealth for patients and informal caregivers confronted with cancer: a meta-review. Int J Med Inform. 2016;87:54–67.

    Article  PubMed  Google Scholar 

  31. McAlpine H, Joubert L, Martin-Sanchez F, Merolli M, Drummond KJ. A systematic review of types and efficacy of online interventions for cancer patients. Patient Educ Couns. 2015;98(3):283–95.

    Article  PubMed  Google Scholar 

  32. Kuijpers W, Groen WG, Oldenburg HS, Wouters MW, Aaronson NK, van Harten WH. eHealth for breast cancer survivors: use, feasibility and impact of an interactive portal. JMIR Cancer. 2016;2(1):e3.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Trompetter HR, Bohlmeijer ET, Veehof MM, Schreurs KMG. Internet-based guided self-help intervention for chronic pain based on Acceptance and Commitment Therapy: a randomized controlled trial. J Behav Med. 2015;38(1):66–80.

    Article  PubMed  Google Scholar 

  34. Veehof MM, Trompetter HR, Bohlmeijer ET, Schreurs KMG. Acceptance-and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. Cogn Behav Ther. 2016;45(1):5–31.

    Article  CAS  PubMed  Google Scholar 

  35. Trompetter HR, Bohlmeijer ET, Lamers SMA, Schreurs KMG. Positive psychological wellbeing is required for online self-help acceptance and commitment therapy for chronic pain to be effective. Front Psychol. 2016;7:353.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lin J, Paganini S, Sander L, Lüking M, Ebert DD, Buhrman M, et al. An internet-based intervention for chronic pain: a three-arm randomized controlled study of the effectiveness of guided and unguided acceptance and commitment therapy. Dtsch Arztebl Int. 2017;114(41):681–8.

    PubMed  PubMed Central  Google Scholar 

  37. Baumeister H, Reichler L, Munzinger M, Lin J. The impact of guidance on Internet-based mental health interventions — a systematic review. Internet Interv. 2014;1(4):205–15.

    Article  Google Scholar 

  38. van de Poll-Franse LV, Horevoorts N, Schoormans D, Beijer S, Ezendam NPM, Husson O, et al. Measuring clinical, biological, and behavioral variables to elucidate trajectories of patient (reported) outcomes: the PROFILES registry. J Natl Cancer Inst. 2022;114(6):800–7.

  39. Lousberg R, Van Breukelen GJP, Groenman NH, Schmidt AJM, Arntz A, Winter FAM. Psychometric properties of the Multidimensional Pain Inventory, Dutch language version (MPI-DLV). Behav Res Ther. 1999;37(2):167–82.

    Article  CAS  PubMed  Google Scholar 

  40. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain. 1985;23(4):345–56.

    Article  PubMed  Google Scholar 

  41. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  42. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135–9.

    Article  CAS  PubMed  Google Scholar 

  43. Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013;22(10):2787–99.

    Article  Google Scholar 

  44. Dworkin RRH, Turk DDCD, Farrar JTJ, Pain JH-, 2005 U, Haythornthwaite JA, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1):9–19.

    Article  PubMed  Google Scholar 

  45. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41(6):1073–93.

    Article  PubMed  Google Scholar 

  46. Spinhoven PH, Ormel J, Sloekers PPA, Kempen GIJM, Speckens AEM, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27:363–70.

    Article  CAS  PubMed  Google Scholar 

  47. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

    Article  CAS  PubMed  Google Scholar 

  48. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7(4):524–32.

    Article  Google Scholar 

  49. Wicksell RK, Olsson GL, Hayes SC. Psychological flexibility as a mediator of improvement in Acceptance and Commitment Therapy for patients with chronic pain following whiplash. Eur J Pain. 2010;14(10):1059.e1–1059.e11.

    Article  Google Scholar 

  50. Wicksell RK, Lekander M, Sorjonen K, Olsson GL. The Psychological Inflexibility in Pain Scale (PIPS) - statistical properties and model fit of an instrument to assess change processes in pain related disability. Eur J Pain. 2010;14(7):771.e1–771.e14.

    Article  Google Scholar 

  51. Trompetter HR, Bohlmeijer ET, Van Baalen B, Kleen M, Köke A, Reneman M, et al. The Psychological Inflexibility in Pain Scale (PIPS) exploration of psychometric properties in a heterogeneous chronic pain sample. Eur J Psychol Assess. 2014;30(4):289–95.

    Article  Google Scholar 

  52. Bruggeman-Everts FZ, Van der Lee ML, Van ‘t Hooft EFM, Nyklíček I. Validation of the Dutch Freiburg Mindfulness Inventory in patients with medical illness. SAGE Open. 2017;7(2):2158244017705936.

    Article  Google Scholar 

  53. Trompetter HR, Ten Klooster PM, Schreurs KMG, Fledderus M, Westerhof GJ, Bohlmeijer ET. Measuring values and committed action with the Engaged Living Scale (ELS): psychometric evaluation in a nonclinical sample and a chronic pain sample. Psychol Assess. 2013;25(4):1235–46.

    Article  PubMed  Google Scholar 

  54. Attkisson CC, Zwick R. The client satisfaction questionnaire. Psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5(3):233–7.

    Article  CAS  PubMed  Google Scholar 

  55. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care Res (Hoboken). 2003;49(2):156–63 Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/art.10993.

    Article  Google Scholar 

  56. Eysenbach G. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011;13:e126.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. New Jersey: Lawrence Erlbaum; 1988.

    Google Scholar 

  58. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21.

    Article  PubMed  Google Scholar 

  59. Turner JA, Holtzman S, Mancl L. Mediators, moderators, and predictors of therapeutic change in cognitive-behavioral therapy for chronic pain. Pain. 2007;127(3):276–86.

    Article  PubMed  Google Scholar 

  60. Hayes A. Introduction to mediation, moderation and conditional process analysis. New York: Guilford Press; 2013.

    Google Scholar 

Download references

Acknowledgements

We would like to thank two patient groups who served as advisors at this project, namely Olijf (Network for Women with Gynecologic Cancer) and BVN (Dutch Breast Cancer Society). Both patient advisory groups provided feedback on the project proposal.

Funding

This study was supported by the Dutch Cancer Society (#12181), 00 31 20 - 570 04 50, bestedingen@kwf.nl. The Dutch Cancer Society had no role in the study design, writing of the manuscript, or submission. Tilburg University is the sponsor of this study.

Author information

Authors and Affiliations

  1. CoRPS - Center of Research on Psychological disorders and Somatic Diseases, Department of Medical and Clinical Psychology, Tilburg University, PO Box 90153, Tilburg, 5000 LE, The Netherlands

    Daniëlle L. van de Graaf, Floortje Mols, Hester R. Trompetter, Marije L. van der Lee & Tom Smeets

  2. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

    Daniëlle L. van de Graaf & Floortje Mols

  3. Centre for Psycho-Oncology, Scientific Research Department, Helen Dowling Institute, Bilthoven, The Netherlands

    Marije L. van der Lee

  4. Department of Psychology, Health & Technology, Centre for eHealth & Well-being Research, University of Twente, Enschede, The Netherlands

    Karlein M. G. Schreurs

  5. Department of Digital Health Research, Division of Medicine, Oslo University Hospital, Oslo, Norway

    Elin Børøsund & Lise Solberg Nes

  6. Faculty of Health and Social Sciences, University of South-Eastern Norway, Drammen, Norway

    Elin Børøsund

  7. Department of Psychiatry and Psychology, College of Medicine and Science, Mayo Clinic, Rochester, MN, USA

    Lise Solberg Nes

  8. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

    Lise Solberg Nes

Authors
  1. Daniëlle L. van de Graaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Floortje Mols
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hester R. Trompetter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marije L. van der Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karlein M. G. Schreurs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elin Børøsund
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lise Solberg Nes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tom Smeets
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FM is principal investigator and developed the study concept and design. HRT is project leader and also developed the study concept and design. DLG is PhD Candidate and wrote the manuscript. TS and MLL contributed to study design. Data collection is coordinated by DLG. FM, HRT, TS and MLL supervise the project. All authors critically revised the manuscript. All authors read and approved the final manuscript.

Investigators: PhD candidate and study coordinator, D.L. van de Graaf; principal investigators and supervisors, F. Mols, T. Smeets, H.R. Trompetter, M.L. van der Lee.

Corresponding author

Correspondence to Daniëlle L. van de Graaf.

Ethics declarations

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Subject information for participation in medicalscientific research.

Additional file 2: Appendix E.

All items from the World Health Organization Trial Registration Data Set.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van de Graaf, D.L., Mols, F., Trompetter, H.R. et al. Effectiveness of the online Acceptance and Commitment Therapy intervention “Embrace Pain” for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy: study protocol for a randomized controlled trial. Trials 23, 642 (2022). https://doi.org/10.1186/s13063-022-06592-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13063-022-06592-3

Keywords

Trials

ISSN: 1745-6215